CN104208705B - A kind of gel for reducing banked blood potassium concentration and its preparation method and application - Google Patents
A kind of gel for reducing banked blood potassium concentration and its preparation method and application Download PDFInfo
- Publication number
- CN104208705B CN104208705B CN201410188555.3A CN201410188555A CN104208705B CN 104208705 B CN104208705 B CN 104208705B CN 201410188555 A CN201410188555 A CN 201410188555A CN 104208705 B CN104208705 B CN 104208705B
- Authority
- CN
- China
- Prior art keywords
- gel
- blood
- kayexalate
- weight portions
- banked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of gel for reducing banked blood potassium concentration and its preparation method and application, described gel includes：The weight portion of kayexalate 3.0 25.0, the weight portion of sodium chloride 0.1 1.5, the auxiliary weight portion of gel 0.1 2.5 and solvent；The step of described preparation method, includes taking kayexalate, sodium chloride, auxiliary gel and solvent, is settled in 100ml water；Repeat-heating 26 times, pours into template solidification when temperature is down to 55 70 DEG C, obtains required gel.After gel of the present invention can be used to make an addition in alserver's solution, and sealing in blood bag is stored in, red cell preservation device is obtained, add the fresh red blood cell for needing to preserve.Gel of the present invention can obviously reduce banked blood Erythrocyte Potassium ion, can also effectively prevent the hyperkalemia caused due to input banked blood to endanger；Described gel is easily prepared and with special stabilizing effect.
Description
Technical field
The present invention relates to medicine technology field of transfusing blood, more particularly to a kind of blood product preservation and processing method, specifically
It is a kind of gel for reducing stock's blood potassium concentration and its preparation method and application.
Background technology
At present, it is clinical to need most of patient of blood transfusion to require supplementation with red blood cell, so the species of red cell preparation is a lot,
Mainly include：Red Blood Cells Suspension, less slurry blood, Red Blood Cells Concentrate, Washed Red Blood Cells, the red blood cell of few leucocyte etc..Generally, it is red thin
Born of the same parents' preparation preserves liquid and preserves using CPAD, and the storage life at 4 DEG C of temperature is 35 days.
But in resting period whole blood too long, red blood cell meeting aging rupture, the potassium ion in cell is discharged into blood,
So as to potassium content is too high in causing serum.Research has shown that red cell preparation with the extension of inventory time, haemocyte cell
Sodium potassium pump (Na on film+-K+- ATP enzyme) will inactivate, cause Potassium In Red Cell ion to outflow, potassium ion is dense in the outer liquid of red blood cell
Degree increases.Potassium ion concentration in the cell is 150mmol/L, and the concentration in serum can remain thin for 3.5-5.5mmol/L
Intracellular exosmosis are pressed and acid-base balance, maintain nervimuscular normal irritability, and potassium is raised, and neuromuscular is excited；And if potassium drops
Low, neuromuscular sinks into paralysis.
Additionally, potassium ion can also be used to maintain the normal irritability of cardiac muscle in serum.Such as when potassium concentration liter in serum
Height, it is myocardium then can be suppressed, cardiac arrest can be made in diastole；If potassium concentration reduction, can produce the rhythm of the heart in serum
Disorder, can make cardiac arrest in the systole phase.
The testing result of stock's Red Blood Cells Suspension extracellular potassium ion is displayed that using existing detection technique：Preserve 7d
Afterwards, potassium concentration is 7.8 ± 0.26mmol/L during Red Blood Cells Suspension preserve liquid, and after preserving 30d, Red Blood Cells Suspension preserve liquid
Middle potassium concentration is 21.0 ± 0.3mmol/L, it is seen that with the increase for preserving number of days, in banked blood, the content of potassium ion is significantly
Increase.Additionally, many clinical researches both at home and abroad are also confirmed that：Banked blood is largely input into if patient, may be gone out with regard to blood donor
Show potassemia, cause a series of harm such as acid-base imbalance.
The annual blood using amount of current China is more than 10,000 tons, and the overwhelming majority uses banked blood.Thus, banked blood hyperkalemia is asked
Topic can not be ignored, it would be highly desirable to solve.Up to the present, blood potassium ion concentration is still stayed in for the research of blood potassium ion concentration to detect
Stage, a kind of method of reagent determination by serum potassium ion enzyme is disclosed in such as patent CN1896271B, and for example patent
A kind of measure serum, the kit of blood plasma potassium concentration are disclosed in CN101717814A；It is existing disclosed literary at home and abroad
In offering, the relevant report for the technology for reducing potassium concentration in banked blood is there is no.
The content of the invention
It is contemplated that in view of the shortcomings of the prior art, there is provided a kind of gel for reducing potassium concentration in banked blood and
Its preparation method and application, to reduce the concentration of potassium ion in banked blood.
The first aspect of the present invention provides a kind of gel for reducing banked blood potassium concentration, and described gel includes：
Kayexalate 3.0-25.0 weight portions, sodium chloride 0.1-1.5 weight portions, auxiliary gel 0.1-2.5 weight
Part and solvent.
Wherein, described solvent is preferably water, and described water can be more preferably distilled water.
Wherein, described gel can also be：
Contain kayexalate 4.0-23.0 weight portions, sodium chloride 0.3-1.2 weight in per 100ml gel solutions
Part, auxiliary gel 0.3-2.3 weight portions.
Described gel can further include：
Contain kayexalate 5.0-20.0 weight portions, sodium chloride 0.6-1.0 weight in per 100ml gel solutions
Part, auxiliary gel 0.5-2.0 weight portions.
Described auxiliary gel can be selected from the one kind in Ago-Gel, glucomannan or polyacrylamide gel
Or it is several.
In the present invention one more in preferred embodiment, described polystyrolsulfon acid receives preferably sodium formula polystyrene
Sodium sulfonate.
In one of the invention more preferred embodiment, the auxiliary gel is most preferably Ago-Gel.
Described Ago-Gel is linear polymer, and basic structure is 1, the 3 β-D- galas furanoses and Isosorbide-5-Nitrae for linking
3, the 6- for linking is dehydrated α-L- gala furanoses, and the molecular formula of the Ago-Gel is：C24H38O19, molecular weight is：630.5.
Ago-Gel is placed in water and is heated to more than 90 DEG C and is dissolved, good half is formed when temperature drop is to 35-40 DEG C solid
Body shape gel.
In one of the invention more preferred embodiment, described water is preferably distilled water.
The second aspect of the present invention provides a kind of preparation method of the gel for reducing banked blood potassium concentration, specific step
It is rapid as follows：
Take kayexalate 3.0-25.0 weight portions, sodium chloride 0.1-1.5 weight portions and auxiliary gel 0.1-2.5
Weight portion and solvent are settled in 100ml water；
Repeat-heating 2-6 times, pours into template solidification when temperature is down to 55-70 DEG C, obtains required gel.
The preparation method of above-mentioned gel, during described Repeat-heating, the heating-up temperature of heating is 80- every time
100 DEG C, and keep temperature 3-7s, Repeat-heating 2-6 times；
Above-mentioned gel temperature after heating is poured into template when temperature is down to 55 DEG C -70 DEG C, treats its natural coagulation, is obtained
Required gel.
The third aspect of the present invention provides a kind of application of the gel of above-mentioned reduced banked blood potassium concentration：Institute
During gel is stated for making an addition to alserver's solution, the alserver's solution containing the gel is obtained.The present invention one compared with
In for preferred embodiment, by the fresh red blood cell of the alserver's solution addition containing gel of the present invention, it is placed in
Preserved in the environment of 3-5 DEG C (more preferably 4 DEG C).
In one of the invention more preferred embodiment, described alserver's solution is the preservation containing sodium citrate
Liquid, such as CPDA preserve liquid, wherein, described CPDA preserves liquid includes sodium citrate, citric acid, glucose, adenine, di(2-ethylhexyl)phosphate
Hydrogen sodium mixes with water.
Above-mentioned application also includes, during the gel made an addition into alserver's solution, and is stored in blood bag and seals, system
The red cell preservation device of the gel must be contained；
Preferably, and in the red cell preservation device containing gel of the present invention fresh red blood cell, juxtaposition are added
Red cell preservation is carried out in the environment of 3-5 DEG C (more preferably 4 DEG C).
Wherein, described red cell preservation device can be used to reduce banked blood potassium ion.
Preferably, described gel and the mass volume ratio (w/v) of alserver's solution are (1：5)-(1：60) it is, described
Gel can also be (1 with the mass volume ratio (w/v) of alserver's solution：10)-(1：50), described gel and red cell preservation
The mass volume ratio (w/v) of liquid can also be more preferably (1：10)-(1：20).
The application for reducing banked blood potassium concentration gel of the present invention, with sodium formula styrene type sodium sulfonate
(sodium polystyrene sulfonate, SPS) is prepared into sodium formula styrene type sulfonic acid sodium resin half with Ago-Gel
Solid gel, using ion exchange (K+-Na+Exchange) principle, by slow and lasting K+-Na+Exchange interaction and reduce storehouse
The potassium ion of blood is deposited, so as to play reduction blood potassium effect.
The effect of the obvious reduction stock Erythrocyte Potassium ion that gel of the present invention has, can effectively prevent due to
The hyperkalemia that input banked blood causes endangers.Described gel is easily prepared and with special stabilizing effect, can be widely used for
The collection of blood, using field, to operator and receptor's safety non-toxic, have no side effect.
Specific embodiment
With reference to specific embodiment, the present invention will be further described, but not as limiting to the invention.
Embodiment 1
The step of preparing a kind of sodium formula kayexalate gel of reduction banked blood potassium concentration is as follows：
Kayexalate 10.0g, sodium chloride 1.0g and Ago-Gel 2.5g are taken, is settled in 100ml water；Plus
Heat is to 100 DEG C and maintains 3 seconds, and Repeat-heating 3 times is poured into square template when temperature is down to 60 DEG C, treats its natural coagulation, system
Obtain required gel.
Embodiment 2
The step of preparing a kind of sodium formula kayexalate gel of reduction banked blood potassium concentration is as follows：
Kayexalate 15.0g, sodium chloride 1.0g and Ago-Gel 2.0g are taken, is settled in 100ml water；Plus
Heat is to 100 DEG C and maintains 5 seconds, and Repeat-heating 4 times is poured into square template when temperature is down to 70 DEG C, treats its natural coagulation, system
Obtain required gel.
Embodiment 3
The step of preparing a kind of sodium formula kayexalate gel of reduction banked blood potassium concentration is as follows：
Kayexalate 5.0g, sodium chloride 0.6g and Ago-Gel 0.5g are taken, is settled in 100ml water；Plus
Heat is to 100 DEG C and maintains 4 seconds, and Repeat-heating 2 times is poured into square template when temperature is down to 55 DEG C, treats its natural coagulation, system
Obtain required gel.
Embodiment 4
Prepare it is a kind of reduce banked blood potassium concentration red cell preservation device the step of it is as follows：
Obtained sodium formula kayexalate gel 25g in embodiment 1 is weighed to be added to during CPDA preserves liquid, make gel with
The mass volume ratio (w/v) that CPDA preserves liquid is 1：12；
By in gel and CPDA preservation liquid mixture addition blood bags, sealed using heat-sealing machine, prepare red cell preservation
Device.
Wherein, described CPDA preserves liquid for sodium citrate, citric acid, glucose, adenine mix with sodium dihydrogen phosphate
The sterile water solution being made.
Embodiment 5
Prepare it is a kind of reduce banked blood potassium concentration red cell preservation device the step of it is as follows：
Obtained sodium formula kayexalate gel 5g in embodiment 2 is weighed to be added to during CPDA preserves liquid, make gel with
The mass volume ratio (w/v) that CPDA preserves liquid is 1：15；
By in gel and CPDA preservation liquid mixture addition blood bags, sealed using heat-sealing machine, prepare red cell preservation
Device.
Wherein, described CPDA preserves liquid for sodium citrate, citric acid, glucose, adenine mix with sodium dihydrogen phosphate
The sterile water solution being made.
Embodiment 6
Prepare it is a kind of reduce banked blood potassium concentration red cell preservation device the step of it is as follows：
Obtained sodium formula kayexalate gel 50g in embodiment 3 is weighed to be added to during CPDA preserves liquid, make gel with
The mass volume ratio (w/v) that CPDA preserves liquid is 1：10；
By in gel and CPDA preservation liquid mixture addition blood bags, sealed using heat-sealing machine, prepare red cell preservation
Device.
Wherein, described CPDA preserves liquid for sodium citrate, citric acid, glucose, adenine mix with sodium dihydrogen phosphate
The sterile water solution being made.
Embodiment 7
The gelling performance test experience of the reduction banked blood potassium concentration described in the embodiment of the present invention
Experimental technique：
Using the red cell preservation device described in embodiment 4,5 parts of fresh Red Blood Cells Suspension, respectively experimental group are preserved
1-5；It is right that the another CPDA taken without gel of the present invention preserve liquid to be used to preserve corresponding identical 5 parts fresh Red Blood Cells Suspension
According to a group 1-5；
Above-mentioned experimental group 1-5, control group are placed in after preserving 28d under same environment, it is same new by above-mentioned 5 parts
Fresh Red Blood Cells Suspension centrifuging and taking supernatant, and using ion selective electrode method on automatic clinical chemistry analyzer (ROCHE DDP)
The concentration of potassium ion in serum is determined, is compared with control group.
Experimental result：
As shown in table 1.
The 28d banked blood blood potassium measurement result tables of comparisons of table 1, experimental group 1-5 and control group 1-5
Interpretation：
Be can be seen that compared with control group 1-5 according to the 28d banked blood blood potassium measurement results shown in table 1, experimental group 1-
Concentration of blood kalium is significantly reduced in 5.Concentration of blood kalium such as experimental group 1 is only 4-6mmol/L, only the concentration of blood kalium of control group 1
About the 1/4 of 17.8mmol/L；And for example the concentration of blood kalium in experimental group 4 is only 5.8mmol/L, and the concentration of blood kalium of control group 4 reaches
20.3mmol/L is arrived, concentration of blood kalium reaches 14.5mmol/L with the difference of concentration of blood kalium in control group 4 in experimental group 4.
It can be seen that, the red cell preservation device added after the sodium formula kayexalate gel described in embodiment 4 can
Effectively to reduce the concentration of blood kalium of banked blood, and the sodium formula kayexalate gel of gained is for reducing storehouse in embodiment 1
Depositing blood concentration of blood kalium has significant effect.
Specific embodiment of the invention has been described in detail above, but it is only used as example, and the present invention is not intended to limit
In particular embodiments described above.To those skilled in the art, any equivalent modifications carried out to the practicality and replace
In generation, is also all among scope of the invention.Therefore, the equalization made without departing from the spirit and scope of the invention is converted and repaiied
Change, all should be contained within the scope of the invention.
Claims (9)
1. it is a kind of reduce banked blood potassium concentration gel, it is characterised in that described gel includes：
Kayexalate 3.0-25.0 weight portions, sodium chloride 0.1-1.5 weight portions, auxiliary gel 0.1-2.5 weight portions with
And solvent；
Described auxiliary gel is selected from one or more in Ago-Gel, glucomannan or polyacrylamide gel.
2. the gel according to claim 1, it is characterised in that the solvent is water.
3. a kind of method for preparing gel as claimed in claim 1, it is characterised in that specific steps include：
Take kayexalate 3.0-25.0 weight portions, sodium chloride 0.1-1.5 weight portions and auxiliary gel 0.1-2.5 weight
Part and solvent are settled to 100ml；
Repeat-heating 2-6 times, pours into template solidification when temperature is down to 55-70 DEG C, obtains required gel.
4. the method according to claim 3, it is characterised in that in the Repeat-heating, the every time heating-up temperature of heating
It is 80-110 DEG C, and keeps temperature 3-7s.
5. a kind of application of gel as claimed in claim 1, it is characterised in that the gel is used to make an addition to red cell preservation
In liquid.
6. the application according to claim 5, it is characterised in that the alserver's solution is the guarantor containing sodium citrate
Liquid storage.
7. the application according to claim 6, it is characterised in that the mass body of the gel and the alserver's solution
Product is than being (1：5)-(1：60).
8. the application according to claim 5, it is characterised in that also including the gel and alserver's solution are stored
Sealed in blood bag, the red cell preservation device containing gel is obtained.
9. the application according to claim 8, it is characterised in that be additionally included in the described red cell preservation containing gel
Red blood cell is added in device, red cell preservation is carried out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410188555.3A CN104208705B (en) | 2014-05-06 | 2014-05-06 | A kind of gel for reducing banked blood potassium concentration and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410188555.3A CN104208705B (en) | 2014-05-06 | 2014-05-06 | A kind of gel for reducing banked blood potassium concentration and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104208705A CN104208705A (en) | 2014-12-17 |
| CN104208705B true CN104208705B (en) | 2017-07-07 |
Family
ID=52090876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410188555.3A Active CN104208705B (en) | 2014-05-06 | 2014-05-06 | A kind of gel for reducing banked blood potassium concentration and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208705B (en) |
-
2014
- 2014-05-06 CN CN201410188555.3A patent/CN104208705B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 李耀杰 等.中心血站库存全血钾离子浓度变化的动态观察.《宁夏医学杂志》.1997,第19卷(第3期),155-156页. * |
| 王志宏 等.降血钾树脂的临床应用.《中国药师》.1999,第2卷(第1期),29页左栏. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104208705A (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102013731B1 (en) | Method for stabilising suspensions of red blood cells encapsulating an active ingredient, the suspensions obtained | |
| Singh et al. | Quality assessment of platelet concentrates prepared by platelet rich plasma-platelet concentrate, buffy coat poor-platelet concentrate (BC-PC) and apheresis-PC methods | |
| Furano et al. | The uptake of biogenic amines by mast cells of the rat | |
| Reikvam et al. | The Mirasol® Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution | |
| Thibault et al. | Characterization of blood components prepared from whole‐blood donations after a 24‐hour hold with the platelet‐rich plasma method | |
| CN103893205A (en) | Cardioplegic solution containing lidocaine and adenosine and preparation method thereof | |
| CN106771261A (en) | The preparation method and its quality-control product of glycosylated hemoglobin quality-control product | |
| JP2016529283A5 (en) | ||
| CN107376427A (en) | A kind of platelet rich plasma preparation method without exogenous additive | |
| JP2016508501A5 (en) | ||
| Wang et al. | Comparison of the effects of three cell saver devices on erythrocyte function during cardiopulmonary bypass procedure—a pilot study | |
| Sputtek | Cryopreservation of red blood cells and platelets | |
| CN101181302A (en) | Upkeep liquid as well as preservative fluid for plastocyte | |
| CN104208705B (en) | A kind of gel for reducing banked blood potassium concentration and its preparation method and application | |
| CN109588613A (en) | A kind of liquid nisin preparation method | |
| CN112921027A (en) | Method for improving thermal stability of nattokinase by immobilization | |
| CN102620950B (en) | Platelet preserving agent | |
| CN205460112U (en) | Separator is gathered to full -automatic whole blood | |
| Izadpanahi et al. | Evaluation of biochemical parameters of platelet concentrates stored in plasma or in a platelet additive solution (Composol) | |
| Högman et al. | Studies on the Mechanism of Human Red Cell Loss of Viability during Storage at+ 4° C in vitro | |
| CN102373178B (en) | Method for preparing suspension red blood cells by using insufficient amount of blood | |
| de Wit et al. | Influence of the primary anticoagulant on the recovery of factor VIII in cryoprecipitate | |
| AuBuchon | Pathogen reduction technologies: what are the concerns? | |
| WO2011093697A1 (en) | Method for determining the reliability of a device for measuring the concentration of a substance in whole blood, method for treating whole blood, container and kit | |
| De Jonge et al. | Metabolic aspects and viability of heparin/CPDA-1-stored red cell concentrate as a by-product of a high yield factor VIII production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |